BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 26306024)

  • 1. [Renal impairment in patients with thromboembolic event: prevalence and clinical implications. A systematic review of the literature].
    Wilke T; Wehling M; Amann S; Bauersachs RM; Böttger B
    Dtsch Med Wochenschr; 2015 Aug; 140(17):e166-74. PubMed ID: 26306024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings.
    Nutescu EA; Spinler SA; Wittkowsky A; Dager WE
    Ann Pharmacother; 2009 Jun; 43(6):1064-83. PubMed ID: 19458109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety profile of tinzaparin versus subcutaneous unfractionated heparin in elderly patients with impaired renal function treated for acute deep vein thrombosis: the Innohep® in Renal Insufficiency Study (IRIS).
    Leizorovicz A; Siguret V; Mottier D; ; Leizorovicz A; Siguret V; Mottier D; Clonier F; Janas M; Stinson J; Townshend G; Maddalena M
    Thromb Res; 2011 Jul; 128(1):27-34. PubMed ID: 21477846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency.
    Lim W; Dentali F; Eikelboom JW; Crowther MA
    Ann Intern Med; 2006 May; 144(9):673-84. PubMed ID: 16670137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The risk of bleeding associated with low molecular weight heparin in patients with renal failure].
    Lai S; Barbano B; Cianci R; Gigante A; Di Donato D; Asllanaj B; Dimko M; Mariotti A; Morabito S; Pugliese F
    G Ital Nefrol; 2010; 27(6):649-54. PubMed ID: 21132647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-molecular-weight heparin (LMWH) in the treatment of thrombosis.
    Holzheimer RG
    Eur J Med Res; 2004 Apr; 9(4):225-39. PubMed ID: 15210403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bridging of oral anticoagulation with low-molecular-weight heparin: experience in 373 patients with renal insufficiency undergoing invasive procedures.
    Hammerstingl C; Omran H;
    Thromb Haemost; 2009 Jun; 101(6):1085-90. PubMed ID: 19492151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
    Bates SM; Greer IA; Pabinger I; Sofaer S; Hirsh J
    Chest; 2008 Jun; 133(6 Suppl):844S-886S. PubMed ID: 18574280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tinzaparin for venous thromboembolism in patients with renal impairment: a single-centre, prospective pilot study.
    Yeung J; Dix CHK; Ritchie AG; Kow M; Chen VMY
    Intern Med J; 2023 Jan; 53(1):68-73. PubMed ID: 32786035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Venous thromboembolism in cancer patients.
    Deng A; Galanis T; Graham MG
    Hosp Pract (1995); 2014 Dec; 42(5):24-33. PubMed ID: 25485915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-molecular-weight-heparins as periprocedural anticoagulation for patients on long-term warfarin therapy: a standardized bridging therapy protocol.
    Jaffer AK; Ahmed M; Brotman DJ; Bragg L; Seshadri N; Qadeer MA; Klein A
    J Thromb Thrombolysis; 2005 Aug; 20(1):11-6. PubMed ID: 16133889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low molecular weight heparins in patients with renal insufficiency.
    Symes J
    CANNT J; 2008; 18(2):55-61. PubMed ID: 18669012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcomes and adherence to guideline recommendations during the initial treatment of acute venous thromboembolism.
    Martinez K; Kosirog E; Billups SJ; Clark NP; Delate T; Witt DM
    Ann Pharmacother; 2015 Aug; 49(8):869-75. PubMed ID: 25931575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.
    Kanaan AO; Silva MA; Donovan JL; Roy T; Al-Homsi AS
    Clin Ther; 2007 Nov; 29(11):2395-405. PubMed ID: 18158080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A systematic review on the accumulation of prophylactic dosages of low-molecular-weight heparins (LMWHs) in patients with renal insufficiency.
    Atiq F; van den Bemt PM; Leebeek FW; van Gelder T; Versmissen J
    Eur J Clin Pharmacol; 2015 Aug; 71(8):921-9. PubMed ID: 26071276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extended Anticoagulant and Aspirin Treatment for the Secondary Prevention of Thromboembolic Disease: A Systematic Review and Meta-Analysis.
    Marik PE; Cavallazzi R
    PLoS One; 2015; 10(11):e0143252. PubMed ID: 26587983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Venous thromboembolism in centenarians: Findings from the RIETE registry.
    Lacruz B; Tiberio G; Núñez MJ; López-Jiménez L; Riera-Mestre A; Tiraferri E; Verhamme P; Mazzolai L; González J; Monreal M;
    Eur J Intern Med; 2016 Dec; 36():62-66. PubMed ID: 27495947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-molecular-weight heparin use in the obese, elderly, and in renal insufficiency.
    Clark NP
    Thromb Res; 2008; 123 Suppl 1():S58-61. PubMed ID: 18809206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deep venous thrombosis and pulmonary embolism. Part 1. Initial treatment: usually a low-molecular-weight heparin.
    Prescrire Int; 2013 Apr; 22(137):99-101, 103-4. PubMed ID: 23662321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LMWH in cancer patients with renal impairment - better than warfarin?
    Bauersachs RM
    Thromb Res; 2016 Apr; 140 Suppl 1():S160-4. PubMed ID: 27067971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.